| Followers | 13 |
| Posts | 471 |
| Boards Moderated | 0 |
| Alias Born | 09/21/2017 |
Thursday, December 07, 2017 4:32:26 AM
I think they got it down to about $1-1.5m per month. I'm actually looking at some news before the ASM to appease the shareholders. With some positive news and only awaiting TOP line, I believe the $12m (plus perhaps paying off some pressing AP to Contractors and suppliers), it should see them through to at least the next 2Qs.
No basis in fact or knowledge but I believe they should have a lock and TOP line results within the next 60 days. I think they are looking for a "slam dunk" type of result to announce. Given the "crappy" trial results of Avastin and yet get full approval.... the bar won't be too hard to jump over.
The management have been dotting the "i"s, crossing the "t"s and other "Housekeeping" loose ends like the settlements of the frivolous suits. From the looks of it, this $12m may be their last raise. With positive news, a partnership or two will be on the cards. I always akin their DC platform to be something like Apple's IOS, license out the tech for the App Developers and collect the royalties and fees. LP is not stupid enough to want to keep everything in house....too many different types of cancers around to want to keep the whole cancer market to Nwbo.. No resources, no sales network, no medical institution penetration, no international distribution network. Why reinvent the wheel? Just collect the tech fees! They can then hope for upfront fees and milestone payments moving forward.
Optimistic? Hell YES, we are at month 28 since August 5 2015, The odds are in our favour for a slam dunk OS. We have Direct to take us forward after the platform is proven through L's approval.
Feeling positive....YES....Dumping Hell NO...been around this biotech stocks many times before and I smell a winner!
Observing the price action since the last 2 PRs, I think the market thinks so too. The price seems to be pretty resilient given the size of the 2 dilutions and (pure speculation on my part), the price play seems to be accumulation from weak hands and probably "daring" the shorts that their play time is over because a "big boy" can absorb whatever you throw their way and can bring the EOD price back to the previous day's or at least close to it.
That's why if they ask for a YES, I'd give them a chance because it's the only logical and rational decision sans emotion and not have a "hole" on my face where my nose used to be!
GLTALs.
No basis in fact or knowledge but I believe they should have a lock and TOP line results within the next 60 days. I think they are looking for a "slam dunk" type of result to announce. Given the "crappy" trial results of Avastin and yet get full approval.... the bar won't be too hard to jump over.
The management have been dotting the "i"s, crossing the "t"s and other "Housekeeping" loose ends like the settlements of the frivolous suits. From the looks of it, this $12m may be their last raise. With positive news, a partnership or two will be on the cards. I always akin their DC platform to be something like Apple's IOS, license out the tech for the App Developers and collect the royalties and fees. LP is not stupid enough to want to keep everything in house....too many different types of cancers around to want to keep the whole cancer market to Nwbo.. No resources, no sales network, no medical institution penetration, no international distribution network. Why reinvent the wheel? Just collect the tech fees! They can then hope for upfront fees and milestone payments moving forward.
Optimistic? Hell YES, we are at month 28 since August 5 2015, The odds are in our favour for a slam dunk OS. We have Direct to take us forward after the platform is proven through L's approval.
Feeling positive....YES....Dumping Hell NO...been around this biotech stocks many times before and I smell a winner!
Observing the price action since the last 2 PRs, I think the market thinks so too. The price seems to be pretty resilient given the size of the 2 dilutions and (pure speculation on my part), the price play seems to be accumulation from weak hands and probably "daring" the shorts that their play time is over because a "big boy" can absorb whatever you throw their way and can bring the EOD price back to the previous day's or at least close to it.
That's why if they ask for a YES, I'd give them a chance because it's the only logical and rational decision sans emotion and not have a "hole" on my face where my nose used to be!
GLTALs.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
